Table 2 Counts of circulating PD-1+ and TIM-3+ T cell subsets in multiple myeloma patients.

From: Quantitative and functional characteristics of circulating and bone marrow PD-1- and TIM-3-positive T cells in treated multiple myeloma patients

Cell subset

Healthy donors (n = 28)

Patients in CR/PR (n = 50)

Patients with progressive disease (n = 10)

CD4+PD-1+, %

4.4 (2.6–5.3)

6.1 (4.7–9.8)*

11.8 (7.3–13.4)*#

CD4+TIM-3+, %

0.6 (0.4–1.0)

1.3 (0.8–2.3)*

2.0 (1.2–2.5)*

CD8+PD-1+, %

1.6 (1.1–3.2)

2.9 (1.6–4.1)*

3.9 (1.3–12.2)*

CD8+TIM-3+, %

3.1 (1.8–5.4)

3.8 (2.4–5.7)*

8.9 (4.8–12.0)*#

  1. Relative counts are presented as the percentages of lymphocytes.
  2. Data are presented as median (interquartile range). P values are assessed with Mann–Whitney U-test.
  3. CR complete remission; PR partial response.
  4. *PU < 0.05 between healthy donors and patients.
  5. #PU < 0.05 between patients in CR/PR and patients with progressive disease.
Back to article page